Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group’s...
February 04 2016 - 4:05PM
StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey,
President and CEO of StemCells, Inc., will participate on a
regenerative medicine panel at Source Capital Group’s 2016
Disruptive Growth and Healthcare Conference. The panel will take
place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the
Convene Conference Center, 730 3rd Avenue, in New York City. The
panel will be moderated by Todd Fromer, principal of KCSA Strategic
Communications. Other panel members will include Adi Mohanty,
Co-CEO, BioTime, Karine Kleinhaus, Div. VP, N.A., Pluristem
Therapeutics, Dan Goldberger, CEO, Xtant Medical, and Mark Hedrick,
MD, CEO, Cytori Therapeutics.
About Source Capital Group
Source Capital Group, Inc. was founded in 1992
on the belief that the best investment advice should be
independent, unbiased and tailor-made for the individual client’s
needs. Source Capital began as a boutique investment banking
firm specializing in small to medium sized transactions. We have
grown to include businesses in general securities, emerging market
securities, distressed and high yield debt securities, in addition
to our investment banking
activity. http://www.sourcegrp.com/.
About StemCells, Inc.
StemCells, Inc. is currently engaged in clinical
development of its HuCNS-SC platform technology (purified human
neural stem cells) as a potential treatment for chronic spinal cord
injury (SCI). The Company's Pathway Study, a Phase II
proof-of-concept trial in cervical SCI is actively enrolling at
twelve sites. Six-month interim data for the first cohort of the
Pathway Study showed the first-ever clinical evidence of a
treatment effect improving both muscle strength and motor function
following cellular transplant in spinal cord injury. Top-line data
from the Company's Phase I/II clinical trial in thoracic SCI showed
measurable gains involving multiple sensory modalities and
segments, including the conversion of two of seven patients
enrolled in the study with complete injuries to incomplete
injuries, post-transplant. The Company has also completed its Phase
I/II clinical trial in geographic atrophy dry age related macular
degeneration. Top-line results from this study show a positive
safety profile and favorable preliminary efficacy data. In a Phase
I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company showed preliminary
evidence of progressive and durable donor-derived myelination by
MRI.
Further information about StemCells, Inc. is
available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the
text of this press release constitutes forward-looking statements
within the meaning of the U.S. securities laws, and is subject to
the safe harbors created therein. These forward-looking statements
speak only as of the date of this news release. The Company does
not undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
Such statements reflect management's current views and are based on
certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks and
uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2014 and in its
subsequent reports on Forms 10-Q and 8-K.
CONTACT:
Greg Schiffman, Chief Financial Officer
StemCells, Inc.
(510) 456-4128
Lena Evans
Russo Partners
(212) 845-4262
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024